

CELGENE CORP /DE/  
Form 8-K  
February 21, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 20, 2008**

**CELGENE CORPORATION**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>0-16132</b> (Commission File Number)	<b>22-2711928</b> (IRS Employer Identification No.)
--	--	--

<b>86 Morris Avenue, Summit, New Jersey</b> (Address of Principal Executive Offices)	<b>07901</b> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: **(908) 673-9000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS**

On February 20, 2008, Celgene Corporation announced a worldwide strategic collaboration with Acceleron Pharma, Inc. for the development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The companies also signed an option agreement for certain discovery stage programs.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 Press Release dated February 20, 2008

This exhibit is furnished pursuant to Item 8.01 and shall not be deemed to be filed.

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: February 21, 2008

By: /s/ David W. Gryska  
Name: David W. Gryska  
Title: Senior Vice President and  
Chief Financial Officer